Obagi Medical Products Announces Publication of Study in the July Edition of the Aesthetic Surgery Journal

LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the publication of a study showing that the use of its Condition & Enhance System (also marketed as Nu-Derm), when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo. Obagi’s Condition & Enhance System is referred to as “a Hydroquinone Skin Care System Plus Tretinoin” in the report.

“This data clearly highlights the fact that by adding Condition & Enhance to injectable patients’ treatment regimen, patients are addressing multiple aspects of aging skin for optimal results. The results prove that, even in patients who have previously had BOTOX, there is room for improvement.”

“I was pleased to have this study published in the Aesthetic Surgery Journal because many of my patients have aged skin that doesn’t always look markedly improved with injectables alone. Many practitioners are not aware of the potential benefits associated with incorporating this system with other non-invasive procedures in the practice,” said Joel Schlessinger, MD, board certified dermatologist from Omaha, Neb., President of LovelySkin, and lead investigator of the study. “This data clearly highlights the fact that by adding Condition & Enhance to injectable patients’ treatment regimen, patients are addressing multiple aspects of aging skin for optimal results. The results prove that, even in patients who have previously had BOTOX, there is room for improvement.”

The Condition & Enhance System was clinically proven to increase patient satisfaction: 82 percent of study participants had peers notice a positive change in overall facial appearance, as compared to 16 percent of study participants in the standard skincare group. Study participants also reported the following by the conclusion of the trial (120 days):

89 percent of patients were either Satisfied or Extremely Satisfied with their overall facial appearance, as compared to 12 percent of the standard skincare group
93 percent were Satisfied or Extremely Satisfied with the treatment regimen, as compared to 12 percent of the standard skincare group
100% of study participants using the Condition & Enhance System wished to continue treatment after the close of the study

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash™ Eyelash Solution, Obagi Blue Peel RADIANCE^TM, and Nu-Derm® Sun Shield SPF 50. Visit www.obagi.com for information.

Blue Peel RADIANCE, ELASTILash and Penetrating Therapeutics are trademarks, and Obagi, the Obagi logo, Condition & Enhance, ELASTIderm, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.